Outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer

(NRG Oncology) Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news